In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

Piper Sandler analyst David Amsellem reiterated a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $138.00. The ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...

Shares of Biogen Inc. BIIB shed 1.44% to $141.00 Wednesday, on what proved to be an all-around positive trading session for ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

Biogen ( ($BIIB) ) has issued an update. On January 13, 2025, Biogen Inc. announced the appointment of Sean Godbout as Vice ...

The stock's rise snapped a three-day losing streak.

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and ...

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...